Aclaris Therapeutics (ACRS) Cash & Equivalents (2014 - 2026)
Aclaris Therapeutics (ACRS) reported Cash & Equivalents of $19.17 million for Q2 2026, down 24.5% from $25.4 million a year earlier and down 33.1% from the prior quarter.
Powered by 
Analysis
Aclaris Therapeutics (ACRS) Cash & Equivalents (2014 - 2026) Analysis & Trends
At the end of FY2025, Aclaris Therapeutics posted Cash & Equivalents of $19.96 million, down 18.8% from FY2024.
- Cash & Equivalents has declined for three consecutive years, with a five-year compound annual growth rate of -2.0% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $24.57 million in FY2024 (-38.4%), $39.88 million in FY2023 (-11.9%), $45.28 million in FY2022 (+65.6%) and $27.35 million in FY2021 (+24.0%).
- The Q2 2026 figure ranks as the lowest quarterly Cash & Equivalents since Q3 2016.
- Year over year, Cash & Equivalents has now declined in each of the last four quarters, with an average decline of 14.5% over the last eight quarters.
- The high point for year-over-year Cash & Equivalents in five years was Q3 2021 (growth of 111.1%); the low point was Q2 2023 (a decline of 54.4%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $28.66 million (Q1 2026), $19.96 million (Q4 2025) and $25.26 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Aclaris Therapeutics | 524.34 Mn | 140.71 Mn | 1.41 Mn | 19.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.17 Mn |
| Mar 31, 2026 | 28.66 Mn |
| Dec 31, 2025 | 19.96 Mn |
| Sep 30, 2025 | 25.26 Mn |
| Jun 30, 2025 | 25.40 Mn |
| Mar 31, 2025 | 30.36 Mn |
| Dec 31, 2024 | 24.57 Mn |
| Sep 30, 2024 | 47.65 Mn |
| Jun 30, 2024 | 22.83 Mn |
| Mar 31, 2024 | 35.84 Mn |
| Dec 31, 2023 | 39.88 Mn |
| Sep 30, 2023 | 39.04 Mn |
| Jun 30, 2023 | 31.15 Mn |
| Mar 31, 2023 | 44.72 Mn |
| Dec 31, 2022 | 45.28 Mn |
| Sep 30, 2022 | 61.65 Mn |
| Jun 30, 2022 | 68.26 Mn |
| Mar 31, 2022 | 36.34 Mn |
| Dec 31, 2021 | 27.35 Mn |
| Sep 30, 2021 | 53.60 Mn |
API Access
Aclaris Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ACRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "ACRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ACRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();